NY Fed:
April one-year ahead expected inflation is 3.3%, versus March's 3%.
April three-year ahead expected inflation is 2.8%, versus March's 2.9%.
April five-year ahead expected inflation is 2.8%, versus March's 2.6%.
April year ahead expected home price climb is 3.3%, versus March's 3%.
Year-ahead expected home price climb is the highest since July 2022.
Respondents forecast higher future prices for food, rent, medical care, and gasoline.
Expected future spending levels are on the rise.
$Nasdaq Composite Index(.IXIC.US$ $S&P 500 Index(.SPX.US$ $SPDR S&P 500 ETF(SPY.US$
April one-year ahead expected inflation is 3.3%, versus March's 3%.
April three-year ahead expected inflation is 2.8%, versus March's 2.9%.
April five-year ahead expected inflation is 2.8%, versus March's 2.6%.
April year ahead expected home price climb is 3.3%, versus March's 3%.
Year-ahead expected home price climb is the highest since July 2022.
Respondents forecast higher future prices for food, rent, medical care, and gasoline.
Expected future spending levels are on the rise.
$Nasdaq Composite Index(.IXIC.US$ $S&P 500 Index(.SPX.US$ $SPDR S&P 500 ETF(SPY.US$
3
Short Interest of Life Sciences Companies at a High Point.
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US$ $SPDR S&P Biotech ETF(XBI.US$ $S&P 500 Index(.SPX.US$
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US$ $SPDR S&P Biotech ETF(XBI.US$ $S&P 500 Index(.SPX.US$
3
No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
6
Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
3
1
$Viking Therapeutics(VKTX.US$ $Novo-Nordisk A/S(NVO.US$ $Eli Lilly and Co(LLY.US$
Chart- show major competitors in obesity and subsequent weight loss over time
Pay attention to Duration in weeks
$Viking Therapeutics(VKTX.US$ best in class drug for obesity with best results (weight loss) in least amount of time vs other companies.
⬇️⬇️
Chart- show major competitors in obesity and subsequent weight loss over time
Pay attention to Duration in weeks
$Viking Therapeutics(VKTX.US$ best in class drug for obesity with best results (weight loss) in least amount of time vs other companies.
⬇️⬇️
4
Top companies and drugs by sales in 2023 from Nature Reviews Drug Discovery.
$Eli Lilly and Co(LLY.US$ and $Novo-Nordisk A/S(NVO.US$ are not on the list (they will be next year of course...). Just shows how forward looking our industry is as both have higher market caps than any of the top 10 companies
$Eli Lilly and Co(LLY.US$ and $Novo-Nordisk A/S(NVO.US$ are not on the list (they will be next year of course...). Just shows how forward looking our industry is as both have higher market caps than any of the top 10 companies
4
$Novo-Nordisk A/S(NVO.US$ & $Eli Lilly and Co(LLY.US$ 's MCap increased by $285 bil in Q1 2024 alone, driven mostly by growth of the GLP-1 franchises,
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
4
$Viking Therapeutics(VKTX.US$ obesity market has all the momentum.
Likely suitors:
- $Pfizer(PFE.US$ - just pulled their Ph3 trial from Danuglipron twice daily dosing due to AE’s. Wants in obesity market.
- $Eli Lilly and Co(LLY.US$ - could own the obesity market with $Viking Therapeutics(VKTX.US$ and tirzepatide. Has speculation interest. Approaching $1T market cap soon.
- $Merck & Co(MRK.US$ - currently studying efinopegdutide. Wants a piece of the pie. Could immediately be a major player with...
Likely suitors:
- $Pfizer(PFE.US$ - just pulled their Ph3 trial from Danuglipron twice daily dosing due to AE’s. Wants in obesity market.
- $Eli Lilly and Co(LLY.US$ - could own the obesity market with $Viking Therapeutics(VKTX.US$ and tirzepatide. Has speculation interest. Approaching $1T market cap soon.
- $Merck & Co(MRK.US$ - currently studying efinopegdutide. Wants a piece of the pie. Could immediately be a major player with...
2
NHP data from $Regeneron Pharmaceuticals(REGN.US$ 's new slide deck is very relevant for the weight loss space.
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock(SRRK.US$ and probably also $Biohaven(BHVN.US$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co(LLY.US$ , $Keros Therapeutics(KROS.US$ ...
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock(SRRK.US$ and probably also $Biohaven(BHVN.US$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co(LLY.US$ , $Keros Therapeutics(KROS.US$ ...
3